Kato, Naoya
4 papers on CoChatORCID 0000-0001-5812-2818
Most cited papers
- Verified
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
Qin, S., Chen, M., Cheng, A.-L., Kaseb, A. O., Kudo, M., Lee, H. C., Yopp, A. C., Zhou, J., Wang, L., Wen, X., et al. (2023) · The Lancet
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 545
- Verified
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Llovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2023) · The Lancet Oncology
Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies
Cited by 469
- Verified
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial
Nakachi, K., Ikeda, M., Konishi, M., Nomura, S., Katayama, H., Kataoka, T., Todaka, A., Yanagimoto, H., Morinaga, S., Kobayashi, S., et al. (2023) · The Lancet
Cholangiocarcinoma and Gallbladder Cancer StudiesGallbladder and Bile Duct Disorders
Cited by 258
- Verified
Clinical characteristics and outcomes of primary sclerosing cholangitis and ulcerative colitis in Japanese patients
Kumagai, J., Taida, T., Ogasawara, S., Nakagawa, T., Iino, Y., Shingyoji, A., Ishikawa, K., Akizue, N., Yamato, M., Takahashi, K., et al. (2018) · PLOS ONE
Liver Diseases and ImmunityInflammatory Bowel Disease
Cited by 29
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free